NCT04795869 2023-10-10Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell LymphomaNorthwestern UniversityPhase 2 Withdrawn
NCT04639843 2022-11-04Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell LymphomaNational Institutes of Health Clinical Center (CC)Phase 1 Withdrawn